{"transactions":[{"id":998711,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-11-14T18:41:01.000Z","date":"2025-11-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":403,"price":236.28,"value":95220.84,"ownership":{"direct":true},"balance_after":7123,"source":{"system":"sec-edgar","filing":"0001225208-25-009159","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520825009159/doc4.xml","form_type":"4"}},{"id":998710,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-11-14T18:41:01.000Z","date":"2025-11-13","kind":"grant","planned":false,"acquired":true,"shares":838,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan."}],"balance_after":7526,"source":{"system":"sec-edgar","filing":"0001225208-25-009159","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520825009159/doc4.xml","form_type":"4"}},{"id":1363388,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-11-15T21:16:55.000Z","date":"2024-11-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":556,"price":153.25,"value":85207.0,"ownership":{"direct":true},"balance_after":6688,"source":{"system":"sec-edgar","filing":"0001225208-24-009990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520824009990/doc4.xml","form_type":"4"}},{"id":1363387,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-11-15T21:16:55.000Z","date":"2024-11-14","kind":"grant","planned":false,"acquired":true,"shares":1327,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan."}],"balance_after":7244,"source":{"system":"sec-edgar","filing":"0001225208-24-009990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520824009990/doc4.xml","form_type":"4"}},{"id":1533625,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-04-29T21:17:30.000Z","date":"2024-04-29","kind":"sale","planned":false,"acquired":false,"shares":7044,"price":141.49,"value":996655.56,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is the weighted average price for the transactions on April 29, 2024.  The range of prices for the transactions is from $141.46 to $141.53 per share.  Information regarding the number of shares sold at each separate price will be provided upon request to the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":5917,"source":{"system":"sec-edgar","filing":"0001225208-24-005341","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520824005341/doc4.xml","form_type":"4"}},{"id":1710698,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-12-14T20:59:07.000Z","date":"2023-12-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":382,"price":135.5,"value":51761.0,"ownership":{"direct":true},"balance_after":12961,"source":{"system":"sec-edgar","filing":"0001225208-23-011104","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520823011104/doc4.xml","form_type":"4"}},{"id":1710697,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-12-14T20:59:07.000Z","date":"2023-12-12","kind":"grant","planned":false,"acquired":true,"shares":1525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan."}],"balance_after":13343,"source":{"system":"sec-edgar","filing":"0001225208-23-011104","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520823011104/doc4.xml","form_type":"4"}},{"id":2114189,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2022-11-16T13:22:08.000Z","date":"2022-11-14","kind":"tax_withholding","acquired":false,"shares":428,"price":124.52,"value":53294.56,"ownership":{"direct":true},"balance_after":11818,"source":{"system":"sec-edgar","filing":"0001225208-22-011704","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520822011704/doc4.xml","form_type":"4"}},{"id":2114188,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2022-11-16T13:22:08.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":1709,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan."}],"balance_after":12246,"source":{"system":"sec-edgar","filing":"0001225208-22-011704","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520822011704/doc4.xml","form_type":"4"}},{"id":2224974,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2022-06-21T18:16:46.000Z","date":"2022-06-16","kind":"disposition_to_issuer","acquired":false,"shares":514002,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (\"Mallinckrodt\"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the \"Bankruptcy Code\") in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1)  On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the \"Plan\"), and on June 16, 2022 (the \"Effective Date\"), the Plan became effective and Mallinckrodt emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan."}],"balance_after":0,"derivative":{"exercise_price":22.26,"exercise_date":"2020-04-01","expiration_date":"2029-04-01","underlying":"Ordinary shares","underlying_shares":514002},"source":{"system":"sec-edgar","filing":"0000899243-22-023438","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000089924322023438/doc4.xml","form_type":"4"}},{"id":2224973,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2022-06-21T18:16:46.000Z","date":"2022-06-16","kind":"disposition_to_issuer","acquired":false,"shares":946003,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (\"Mallinckrodt\"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the \"Bankruptcy Code\") in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1)  On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the \"Plan\"), and on June 16, 2022 (the \"Effective Date\"), the Plan became effective and Mallinckrodt emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan."}],"balance_after":0,"derivative":{"exercise_price":13.8,"exercise_date":"2019-04-02","expiration_date":"2028-04-02","underlying":"Ordinary shares","underlying_shares":946003},"source":{"system":"sec-edgar","filing":"0000899243-22-023438","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000089924322023438/doc4.xml","form_type":"4"}},{"id":2224972,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2022-06-21T18:16:46.000Z","date":"2022-06-16","kind":"disposition_to_issuer","acquired":false,"shares":249785,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (\"Mallinckrodt\"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the \"Bankruptcy Code\") in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1)  On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the \"Plan\"), and on June 16, 2022 (the \"Effective Date\"), the Plan became effective and Mallinckrodt emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan."}],"balance_after":0,"derivative":{"exercise_price":51.73,"exercise_date":"2018-01-03","expiration_date":"2027-01-03","underlying":"Ordinary shares","underlying_shares":249785},"source":{"system":"sec-edgar","filing":"0000899243-22-023438","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000089924322023438/doc4.xml","form_type":"4"}},{"id":2224971,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2022-06-21T18:16:46.000Z","date":"2022-06-16","kind":"disposition_to_issuer","acquired":false,"shares":175528,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (\"Mallinckrodt\"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the \"Bankruptcy Code\") in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1)  On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the \"Plan\"), and on June 16, 2022 (the \"Effective Date\"), the Plan became effective and Mallinckrodt emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan."}],"balance_after":0,"derivative":{"exercise_price":72.61,"exercise_date":"2017-01-04","expiration_date":"2026-01-04","underlying":"Ordinary shares","underlying_shares":175528},"source":{"system":"sec-edgar","filing":"0000899243-22-023438","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000089924322023438/doc4.xml","form_type":"4"}},{"id":2224970,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2022-06-21T18:16:46.000Z","date":"2022-06-16","kind":"disposition_to_issuer","acquired":false,"shares":108014,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (\"Mallinckrodt\"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the \"Bankruptcy Code\") in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1)  On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the \"Plan\"), and on June 16, 2022 (the \"Effective Date\"), the Plan became effective and Mallinckrodt emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan."}],"balance_after":0,"derivative":{"exercise_price":96.96,"exercise_date":"2016-01-02","expiration_date":"2025-01-02","underlying":"Ordinary shares","underlying_shares":108014},"source":{"system":"sec-edgar","filing":"0000899243-22-023438","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000089924322023438/doc4.xml","form_type":"4"}},{"id":2224969,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2022-06-21T18:16:46.000Z","date":"2022-06-16","kind":"disposition_to_issuer","acquired":false,"shares":63542,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (\"Mallinckrodt\"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the \"Bankruptcy Code\") in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1)  On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the \"Plan\"), and on June 16, 2022 (the \"Effective Date\"), the Plan became effective and Mallinckrodt emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan."}],"balance_after":0,"derivative":{"exercise_price":51.35,"exercise_date":"2015-01-02","expiration_date":"2024-01-02","underlying":"Ordinary shares","underlying_shares":63542},"source":{"system":"sec-edgar","filing":"0000899243-22-023438","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000089924322023438/doc4.xml","form_type":"4"}},{"id":2224968,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2022-06-21T18:16:46.000Z","date":"2022-06-16","kind":"disposition_to_issuer","acquired":false,"shares":234437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (\"Mallinckrodt\"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the \"Bankruptcy Code\") in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1)  On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the \"Plan\"), and on June 16, 2022 (the \"Effective Date\"), the Plan became effective and Mallinckrodt emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan."}],"balance_after":0,"derivative":{"exercise_price":44,"exercise_date":"2016-07-01","expiration_date":"2023-06-30","underlying":"Ordinary shares","underlying_shares":234437},"source":{"system":"sec-edgar","filing":"0000899243-22-023438","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000089924322023438/doc4.xml","form_type":"4"}},{"id":2224967,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2022-06-21T18:16:46.000Z","date":"2022-06-16","kind":"disposition_to_issuer","acquired":false,"shares":38875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (\"Mallinckrodt\"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the \"Bankruptcy Code\") in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1)  On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the \"Plan\"), and on June 16, 2022 (the \"Effective Date\"), the Plan became effective and Mallinckrodt emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan."}],"balance_after":0,"derivative":{"exercise_price":41.73,"exercise_date":"2013-12-03","expiration_date":"2022-12-02","underlying":"Ordinary shares","underlying_shares":38875},"source":{"system":"sec-edgar","filing":"0000899243-22-023438","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000089924322023438/doc4.xml","form_type":"4"}},{"id":2475144,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2021-12-13T21:40:54.000Z","date":"2021-12-09","kind":"tax_withholding","acquired":false,"shares":312,"price":157.14,"value":49027.68,"ownership":{"direct":true},"balance_after":10537,"source":{"system":"sec-edgar","filing":"0001225208-21-014842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520821014842/doc4.xml","form_type":"4"}},{"id":2475143,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2021-12-13T21:40:54.000Z","date":"2021-12-09","kind":"grant","acquired":true,"shares":1247,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan."}],"balance_after":10849,"source":{"system":"sec-edgar","filing":"0001225208-21-014842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520821014842/doc4.xml","form_type":"4"}},{"id":2979413,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2020-11-16T16:15:59.000Z","date":"2020-11-12","kind":"sale","acquired":false,"shares":217072,"price":0.1262,"value":27394.4864,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents a weighted average. The shares were sold in multiple transactions at prices ranging from $0.125 to $0.1286, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range."}],"balance_after":11312,"source":{"system":"sec-edgar","filing":"0000950138-20-000469","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013820000469/edgar.xml","form_type":"4"}},{"id":2982820,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2020-11-12T21:22:00.000Z","date":"2020-11-09","kind":"tax_withholding","acquired":false,"shares":447,"price":105.86,"value":47319.42,"ownership":{"direct":true},"balance_after":9602,"source":{"system":"sec-edgar","filing":"0001225208-20-013454","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520820013454/doc4.xml","form_type":"4"}},{"id":2982819,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2020-11-12T21:22:00.000Z","date":"2020-11-09","kind":"grant","acquired":true,"shares":1785,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan."}],"balance_after":10049,"source":{"system":"sec-edgar","filing":"0001225208-20-013454","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520820013454/doc4.xml","form_type":"4"}},{"id":3316002,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2020-01-07T20:20:46.000Z","date":"2020-01-04","kind":"tax_withholding","acquired":false,"shares":1843,"price":3.26,"value":6008.18,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 376 shares acquired under the Mallinckrodt employee stock purchase plan."}],"balance_after":228384,"source":{"system":"sec-edgar","filing":"0000950138-20-000021","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013820000021/edgar.xml","form_type":"4"}},{"id":3316001,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2020-01-07T20:20:46.000Z","date":"2020-01-03","kind":"tax_withholding","acquired":false,"shares":3403,"price":3.36,"value":11434.08,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 376 shares acquired under the Mallinckrodt employee stock purchase plan."}],"balance_after":230227,"source":{"system":"sec-edgar","filing":"0000950138-20-000021","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013820000021/edgar.xml","form_type":"4"}},{"id":3372600,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2019-11-13T20:48:07.000Z","date":"2019-11-11","kind":"tax_withholding","acquired":false,"shares":497,"price":93.63,"value":46534.11,"ownership":{"direct":true},"balance_after":8264,"source":{"system":"sec-edgar","filing":"0001225208-19-014451","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520819014451/doc4.xml","form_type":"4"}},{"id":3372599,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2019-11-13T20:48:07.000Z","date":"2019-11-11","kind":"grant","acquired":true,"shares":1988,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan."}],"balance_after":8761,"source":{"system":"sec-edgar","filing":"0001225208-19-014451","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520819014451/doc4.xml","form_type":"4"}},{"id":3506036,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2019-05-31T07:05:15.000Z","date":"2019-05-30","kind":"purchase","acquired":true,"shares":2000,"price":9.264,"value":18528.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $9.24 to $9.28, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range."}],"balance_after":233254,"source":{"system":"sec-edgar","filing":"0000950138-19-000329","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013819000329/edgar.xml","form_type":"4"}},{"id":3531169,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2019-05-10T08:06:15.000Z","date":"2019-05-09","kind":"purchase","acquired":true,"shares":1000,"price":16.325,"value":16325.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $16.31 to $16.34, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,002 shares acquired on March 31, 2019 under the Mallinckrodt employee stock purchase plan."}],"balance_after":231254,"source":{"system":"sec-edgar","filing":"0000950138-19-000298","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013819000298/edgar.xml","form_type":"4"}},{"id":3563799,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2019-04-03T17:36:39.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":514002,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in four equal annual installments beginning April 1, 2020."}],"balance_after":514002,"derivative":{"exercise_price":22.26,"exercise_date":"2020-04-01","expiration_date":"2029-04-01","underlying":"Ordinary Shares","underlying_shares":514002},"source":{"system":"sec-edgar","filing":"0000950138-19-000217","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013819000217/edgar.xml","form_type":"4"}},{"id":3607824,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2019-03-06T08:18:12.000Z","date":"2019-03-05","kind":"purchase","acquired":true,"shares":1000,"price":22.65,"value":22650.0,"ownership":{"direct":true},"balance_after":229252,"source":{"system":"sec-edgar","filing":"0000950138-19-000127","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013819000127/edgar.xml","form_type":"4"}},{"id":3701616,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2019-01-07T17:52:58.000Z","date":"2019-01-04","kind":"tax_withholding","acquired":false,"shares":3184,"price":17.21,"value":54796.64,"ownership":{"direct":true},"balance_after":228252,"source":{"system":"sec-edgar","filing":"0000950138-19-000019","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013819000019/edgar.xml","form_type":"4"}},{"id":3701615,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2019-01-07T17:52:58.000Z","date":"2019-01-03","kind":"tax_withholding","acquired":false,"shares":3773,"price":16.14,"value":60896.22,"ownership":{"direct":true},"balance_after":231436,"source":{"system":"sec-edgar","filing":"0000950138-19-000019","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013819000019/edgar.xml","form_type":"4"}},{"id":3703177,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2019-01-04T17:54:28.000Z","date":"2019-01-02","kind":"tax_withholding","acquired":false,"shares":1045,"price":16.59,"value":17336.55,"ownership":{"direct":true},"balance_after":235209,"source":{"system":"sec-edgar","filing":"0000950138-19-000007","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013819000007/edgar.xml","form_type":"4"}},{"id":3735113,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2018-12-11T08:30:41.000Z","date":"2018-12-10","kind":"purchase","acquired":true,"shares":1000,"price":20.1801,"value":20180.1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $20.15 to $20.19, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1 share acquired on June 30, 2018 under the Mallinckrodt employee stock purchase plan."}],"balance_after":236254,"source":{"system":"sec-edgar","filing":"0000950138-18-000653","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013818000653/edgar.xml","form_type":"4"}},{"id":3766361,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2018-11-13T21:00:23.000Z","date":"2018-11-12","kind":"tax_withholding","acquired":false,"shares":596,"price":76.66,"value":45689.36,"ownership":{"direct":true},"balance_after":6773,"source":{"system":"sec-edgar","filing":"0001225208-18-015454","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520818015454/doc4.xml","form_type":"4"}},{"id":3766360,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2018-11-13T21:00:23.000Z","date":"2018-11-12","kind":"grant","acquired":true,"shares":2381,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan."}],"balance_after":7369,"source":{"system":"sec-edgar","filing":"0001225208-18-015454","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520818015454/doc4.xml","form_type":"4"}},{"id":3874055,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2018-07-03T16:33:00.000Z","date":"2018-07-01","kind":"tax_withholding","acquired":false,"shares":34708,"price":18.66,"value":647651.28,"ownership":{"direct":true},"balance_after":235253,"source":{"system":"sec-edgar","filing":"0000950138-18-000465","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013818000465/edgar.xml","form_type":"4"}},{"id":3925351,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2018-05-18T16:46:40.000Z","date":"2018-05-16","kind":"purchase","acquired":true,"shares":3000,"price":15.5382,"value":46614.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $15.525 to $15.55, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,062 shares acquired on March 31, 2018 under the Mallinckrodt employee stock purchase plan."}],"balance_after":269961,"source":{"system":"sec-edgar","filing":"0000950138-18-000427","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013818000427/edgar.xml","form_type":"4"}},{"id":3969085,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2018-04-04T17:53:45.000Z","date":"2018-04-02","kind":"grant","acquired":true,"shares":946003,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in four equal annual installments beginning April 2, 2019."}],"balance_after":946003,"derivative":{"exercise_price":13.8,"exercise_date":"2019-04-02","expiration_date":"2028-04-02","underlying":"Ordinary Shares","underlying_shares":946003},"source":{"system":"sec-edgar","filing":"0000950138-18-000301","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013818000301/edgar.xml","form_type":"4"}},{"id":4105073,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2018-01-05T19:44:56.000Z","date":"2018-01-04","kind":"tax_withholding","acquired":false,"shares":2644,"price":23.4,"value":61869.6,"ownership":{"direct":true},"balance_after":265899,"source":{"system":"sec-edgar","filing":"0000950138-18-000055","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013818000055/edgar.xml","form_type":"4"}},{"id":4105072,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2018-01-05T19:44:56.000Z","date":"2018-01-03","kind":"tax_withholding","acquired":false,"shares":4370,"price":23.51,"value":102738.7,"ownership":{"direct":true},"balance_after":268543,"source":{"system":"sec-edgar","filing":"0000950138-18-000055","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013818000055/edgar.xml","form_type":"4"}},{"id":4106685,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2018-01-04T19:08:17.000Z","date":"2018-01-02","kind":"tax_withholding","acquired":false,"shares":6511,"price":23.52,"value":153138.72,"ownership":{"direct":true},"balance_after":272913,"source":{"system":"sec-edgar","filing":"0000950138-18-000020","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013818000020/edgar.xml","form_type":"4"}},{"id":4106684,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2018-01-04T19:08:17.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":10046,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Vesting of performance share award granted on January 2, 2015."}],"balance_after":279424,"source":{"system":"sec-edgar","filing":"0000950138-18-000020","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013818000020/edgar.xml","form_type":"4"}},{"id":4163357,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2017-11-14T21:17:59.000Z","date":"2017-11-13","kind":"tax_withholding","acquired":false,"shares":512,"price":93.36,"value":47800.32,"ownership":{"direct":true},"balance_after":4988,"source":{"system":"sec-edgar","filing":"0001225208-17-017303","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520817017303/doc4.xml","form_type":"4"}},{"id":4163356,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2017-11-14T21:17:59.000Z","date":"2017-11-13","kind":"grant","acquired":true,"shares":2048,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of shares by the issuer under directors' compensation program and Issuer's stock and incentive plan."}],"balance_after":5500,"source":{"system":"sec-edgar","filing":"0001225208-17-017303","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520817017303/doc4.xml","form_type":"4"}},{"id":4164999,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2017-11-13T16:14:58.000Z","date":"2017-11-10","kind":"purchase","acquired":true,"shares":5000,"price":22.2803,"value":111401.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $22.21 to $22.32, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 325 shares acquired between April 1, 2017 and September 30, 2017 under the Mallinckrodt employee stock purchase plan."}],"balance_after":269378,"source":{"system":"sec-edgar","filing":"0000950138-17-000752","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013817000752/edgar.xml","form_type":"4"}},{"id":4285057,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2017-06-12T16:22:03.000Z","date":"2017-06-09","kind":"purchase","acquired":true,"shares":1000,"price":40.1735,"value":40173.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $40.13 to $40.205, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 373 shares acquired on March 31, 2017 under the Mallinckrodt employee stock purchase plan."}],"balance_after":264053,"source":{"system":"sec-edgar","filing":"0000950138-17-000480","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013817000480/edgar.xml","form_type":"4"}},{"id":4444986,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2017-02-15T08:49:37.000Z","date":"2017-02-14","kind":"purchase","acquired":true,"shares":1000,"price":50.4664,"value":50466.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $50.45 to $50.49, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 128 shares acquired on December 31, 2016 under the Mallinckrodt employee stock purchase plan."}],"balance_after":262680,"source":{"system":"sec-edgar","filing":"0000950138-17-000174","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013817000174/edgar.xml","form_type":"4"}},{"id":4495971,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2017-01-06T18:09:39.000Z","date":"2017-01-04","kind":"tax_withholding","acquired":false,"shares":3339,"price":53.19,"value":177601.41,"ownership":{"direct":true},"balance_after":261552,"source":{"system":"sec-edgar","filing":"0000950138-17-000049","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013817000049/edgar.xml","form_type":"4"}},{"id":4501558,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2017-01-04T21:00:47.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":249785,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest in four equal annual installments beginning January 3, 2018."}],"balance_after":249785,"derivative":{"exercise_price":51.73,"exercise_date":"2018-01-03","expiration_date":"2027-01-03","underlying":"Ordinary Shares","underlying_shares":249785},"source":{"system":"sec-edgar","filing":"0000950138-17-000017","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013817000017/edgar.xml","form_type":"4"}},{"id":4501557,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2017-01-04T21:00:47.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":3837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted stock units that vest in three equal annual installments beginning January 3, 2018."}],"balance_after":264891,"source":{"system":"sec-edgar","filing":"0000950138-17-000017","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013817000017/edgar.xml","form_type":"4"}},{"id":4501556,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2017-01-04T21:00:47.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":44462,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units that vest in four equal annual installments beginning January 3, 2018."}],"balance_after":261054,"source":{"system":"sec-edgar","filing":"0000950138-17-000017","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013817000017/edgar.xml","form_type":"4"}},{"id":4501555,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2017-01-04T21:00:47.000Z","date":"2017-01-02","kind":"tax_withholding","acquired":false,"shares":22162,"price":49.82,"value":1104110.84,"ownership":{"direct":true},"balance_after":216592,"source":{"system":"sec-edgar","filing":"0000950138-17-000017","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013817000017/edgar.xml","form_type":"4"}},{"id":4501554,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2017-01-04T21:00:47.000Z","date":"2017-01-02","kind":"grant","acquired":true,"shares":47518,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Vesting of performance share award granted on January 2, 2014."}],"balance_after":238754,"source":{"system":"sec-edgar","filing":"0000950138-17-000017","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013817000017/edgar.xml","form_type":"4"}},{"id":4530947,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2016-12-06T08:24:52.000Z","date":"2016-12-03","kind":"tax_withholding","acquired":false,"shares":1566,"price":53.61,"value":83953.26,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 256 shares acquired on September 30, 2016 under the Mallinckrodt employee stock purchase plan."}],"balance_after":191236,"source":{"system":"sec-edgar","filing":"0000950138-16-001493","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540412/000095013816001493/edgar.xml","form_type":"4"}},{"id":4554685,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2016-11-15T21:18:01.000Z","date":"2016-11-14","kind":"tax_withholding","acquired":false,"shares":732,"price":66.74,"value":48853.68,"ownership":{"direct":true},"balance_after":3452,"source":{"system":"sec-edgar","filing":"0001225208-16-041798","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520816041798/doc4.xml","form_type":"4"}},{"id":4554684,"issuer":{"id":3004,"kind":"organization","name":"TE Connectivity plc","symbol":"TEL"},"owners":[{"id":73114,"kind":"person","name":"Trudeau Mark","position":1,"cik":"0001540412","reported_name":"Trudeau Mark","relationship":{"director":true}}],"security":"Common Shares","published_at":"2016-11-15T21:18:01.000Z","date":"2016-11-14","kind":"grant","acquired":true,"shares":2927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan."}],"balance_after":4184,"source":{"system":"sec-edgar","filing":"0001225208-16-041798","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385157/000122520816041798/doc4.xml","form_type":"4"}}]}